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ABSTRACT Eicosanoids are important vascular regu-
lators, but the phospholipase A2 (PLA2) isoforms sup-
porting their production within the cardiovascular system
are not fully understood. To address this, we have studied
platelets, endothelial cells, and leukocytes from 2 siblings
with a homozygous loss-of-functionmutation in group IVA
cytosolic phospholipase A2 (cPLA2a). Chromatography/
mass spectrometry was used to determine levels of a broad
range of eicosanoids produced by isolated vascular cells,
and in plasma and urine. Eicosanoid release data were
paired with studies of cellular function. Absence of
cPLA2a almost abolished eicosanoid synthesis in platelets
(e.g., thromboxane A2, control 20.56 1.4 ng/ml vs. patient
0.1 ng/ml) and leukocytes [e.g., prostaglandin E2 (PGE2),
control 21.9 6 7.4 ng/ml vs. patient 1.9 ng/ml], and this
was associated with impaired platelet activation and en-
hanced inflammatory responses. cPLA2a-deficient endo-
thelial cells showed reduced, but not absent, formation of
prostaglandin I2 (prostacyclin; control 9566 422 pg/ml vs.
patient 196 pg/ml) and were primed for inflammation.
In the urine, prostaglandin metabolites were selectively
influenced by cPLA2a deficiency. For example, prostacy-
clin metabolites were strongly reduced (18.4% of control)
in patients lacking cPLA2a, whereas PGE2 metabolites
(77.8%of control) were similar to healthy volunteer levels.
These studies constitute a definitive account, demonstrat-
ing the fundamental role of cPLA2a to eicosanoid forma-
tion and cellular responseswithin thehumancirculation.—
Kirkby,N. S.,Reed,D.M., Edin,M.L., Rauzi, F.,Mataragka,
S., Vojnovic, I., Bishop-Bailey, D., Milne, G. L., Longhurst,
H., Zeldin, D. C., Mitchell, J. A., Warner, T. D. Inherited
human group IVA cytosolic phospholipase A2 deficiency
abolishes platelet, endothelial, and leucocyte eicosanoid
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In thecardiovascular system,eicosanoidshavewell-characterized
roles in both normal function and a range of disease states
(1, 2). For example, thromboxaneA2 (TXA2), generated by
platelets, drives thrombotic responses to particular stimuli
(e.g., collagen) and contributes to atherogenesis, whereas
prostaglandin I2 (prostacyclin), generated by endothelial
cells, causes vasodilatation, inhibits platelet activation, and
suppresses vascular inflammation. In leukocytes, eicosanoid
formation [predominantly prostaglandin E2 (PGE2)] is in-
duced by proinflammatory stimuli such as LPS that up-
regulate cyclooxygenase (COX)-2 and other biosynthetic
pathways (3) and so modulate the inflammatory response.
In each case, although specific eicosanoid pathways such as
TXA2, PGE2, and prostacyclin are well characterized, plate-
lets, endothelial cells, and leukocytes synthesize substantial
amounts of other arachidonic acid–derived mediators, the
effect of which in combination remains poorly understood.
The arachidonic acid required for eicosanoid pro-
duction is released from the sn-2 position of membrane
Abbreviations: CD31, platelet endothelial cell adhesion mol-
ecule-1; COX, cyclooxygenase; cPLA2, cytosolic phospholipase
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glycerophospholipids by the actions of phospholipase A2
(PLA2) enzymes. As reviewed (4, 5), .30 PLA2 enzymes
have been identified and currently classified into 6 broad
families: secretedphospholipaseA2(sPLA2),Ca
2+-dependent
cytosolic phospholipase A2 (cPLA2), calcium-independent
phospholipase A2 (iPLA2), platelet-activating factor ace-
tylhydrolases, lysosomal PLA2, and adipose-specific phos-
pholipase. Of the known isoforms, group IVA cPLA2 (also
referred to as cPLA2a), encoded by the PLA2G4A gene, is
the most studied and has been characterized as a cytosolic
enzyme, which upon Ca2+-dependent activation cleaves
arachidonate-containing phospholipids to generate free
intracellular arachidonic acid. This arachidonic acid is
then used as a substrate by enzymes that synthesize the
eicosanoid mediators, including COXs that produce
prostanoids such as TXA2 and prostacyclin, lipoxygenases
(LOXs) that generate hydroxyeicosatetraenoic acids (e.g.,
12-HETE), and cytochrome P450 enzymes that generate
epoxyeicosatrienoic acids (EETs) and HETEs (4, 5).
cPLA2a is widely expressed through the vasculature, in
platelets, and in most types of blood leukocytes. Nonethe-
less, vascular and blood cells are known to express other
PLA2 enzymes, such as sPLA2 enzymes including group II
(platelets) and group V (endothelium) isoforms as well as
iPLA2 isoforms, which could also liberate arachidonic acid.
For example, exogenous sPLA2 has been demonstrated to
activate platelets (6, 7) and endothelial cells (8). A role for
endogenous sPLA2 and iPLA2 enzymes in eicosanoid
generation by agonist-stimulated platelets (7, 9, 10), en-
dothelial cells (11, 12), and leukocytes (13, 14) has also
been described by several groups, calling into question the
relative roleof PLA2 isoforms ineicosanoid generationand
vascular protection. Indeed, the recent failure of the sPLA2
inhibitor varespladib for the prevention of cardiovascular
events in patients with acute coronary syndromes under-
lines our inadequate knowledge of the role of PLA2
enzymes in vascular health and disease (15).
The key role of cPLA2a in the generation of eicosanoid
mediators is supported by data from cPLA2a-knockout
mice (9) and pharmacologic inhibitors (16, 17). Further-
more, we have recently reported 2 siblings with a homozy-
gous mutation of the PLA2G4A gene that leads to a
complete absence of cPLA2a activity (18). Our work (18)
and similar work from 2 other groups (19, 20) using tissue
frompatientswithaheterozygousmutationof thePLA2G4A
gene has shown that cPLA2a regulates production of
particular eicosanoids in platelets and in the urine.
However, the relative role of cPLA2a in endothelial cell
and leukocyte eicosanoid function, as well as more
broadly in platelets, has not thus far been addressed. By
performing such studies, we have now definitively de-
fined and compared the contribution of cPLA2a with
eicosanoid formation and inflammatory responses in
leukocytes, platelets, and in endothelial cells. Our data
show, for the first time, how loss of this fundamental
enzyme system regulates phenotypes and inflammatory
responses of these cardiovascular cells and associated
urinary markers relevant to vascular disease.
MATERIALS AND METHODS
Blood collection and ethics
Bloodwas collected by venipuncture fromhealthy volunteers and
from 2 patients (brother, patient B; sister, patient S) bearing
ahomozygousmutation in thePLA2G4Agene,whichdisrupts the
active site of cPLA2a (18). All experiments were subject to written
informed consent, local ethical approval (healthy volunteer
samples for platelet/leukocyte studies; St. Thomas’s Hospital
Research Ethics Committee, reference 07/Q0702/24: endothe-
lial cell studies; Royal Brompton and Harfield Hospital Research
Ethics Committee, reference 08/H0708/69: patient samples;
South East NationalHealth Service Research Ethics Committee),
and in accordance with Declaration of Helsinki principles.
Whole-blood stimulation
Heparin-anticoagulated whole blood was incubated with vehicle
(PBS), Horm collagen (Nycomed, St. Peter, Austria), thrombin
receptor-activating peptide (TRAP)-6 amide (Bachem, Heidel-
berg, Germany), Ca2+ ionophore, A23187 (Sigma-Aldrich, Poole,
United Kingdom), for 30 min, or with LPS (Sigma-Aldrich), tri-
acylated lipoprotein CSK4 (Pam3CSK4; InvivoGen, Toulouse,
France), bisacylated lipoprotein CGDPKHPKSF (FSL-1; Invivo-
Gen), polyinosinic:polycytidylic acid [poly(I:C); Sigma-Aldrich],
or IL-1b (Invitrogen, Life Technologies, Paisley, United King-
dom) for 18 h in the presence or absence of diclofenac (10 mM;
Sigma-Aldrich). Levels of (C-X-C motif) ligand-8 (CXCL8; R&D
Systems, Abingdon, United Kingdom), PGE2 (Cisbio, Saclay,
France), or TXB2 (Cayman Chemical, Cambridge Bioscience,
Cambridge, United Kingdom) were measured by immunoassay
or total eicosanoids by gas chromatography–tandem mass spec-
trometry (see below) in the conditioned plasma.
Eicosanoid analysis
Basal and conditioned plasmawas subject to eicosanomic analysis
as previously described (21). Urinary prostanoid levels were de-
termined by gas chromatography–tandem mass spectrometry as
previously described (22, 23).
Light transmission aggregometry and ATP release
Platelet-rich plasma was preincubated with the COX inhibitor
aspirin (30 mM; Sigma-Aldrich), the cPLA2 inhibitor pyrrophe-
none (40 mM; Cayman Chemical, Cambridge Bioscience), or
vehicle for 30 min at 37°C. Aggregation and ATP secretion re-
sponses to collagen (0.3–3 mg/ml), ADP (5 mM; Chrono-log;
Labmedics, Abingdon, United Kingdom), U46619 (10mM; Enzo
Life Sciences, Exeter, United Kingdom), or arachidonic acid
(1mM; Sigma-Aldrich)weremeasured using aChrono-log 560CA
Lumi-Aggregometer (Chrono-logCorp.,Havertown, PA,USA).
Platelet adhesion under flow
Whole blood was preincubated with aspirin (100 mM), pyrro-
phenone (40 mM), or vehicle before labeling of cells with
(continued from previous page)
phospholipase A2; LOX, lipoxygenase; LTE4, leukotriene E4;
Pam3CSK4, triacylated lipoprotein CSK4; PAMP, pathogen-
associated molecular pattern; PGD2, prostaglandin D2; PGE2,
prostaglandin E2; PLA2, phospholipase A2; Poly(I:C), polyinosinic:
polycytidylic acid; prostacyclin, prostaglandin I2; sPLA2, secreted
phospholipase A2; TRAP, thrombin receptor-activating peptide;
TXA2, thromboxane A2; TX-M, metabolite of thromboxane A2
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mepacrine (10mM; Sigma-Aldrich) for a further 30min. This was
then drawn through a slide chamber (Ibidi, Munich, Germany)
coated with collagen (100 mg/ml) by a syringe pump to achieve
a shear rate of 1000 s21.
Endothelial cells
Blood outgrowth endothelial cells were grown out from progen-
itors in human blood as previously described (24–27). Once
colonies emerged (betweend 4 and20), cells were expanded and
maintained in Lonza EGM-2 medium (Lonza, Slough, United
Kingdom) plus 10% fetal bovine serum, and experiments were
performed between passages 2 and 8.
Endothelial cell immunocytochemistry
Endothelial cells were stained using anti-CD31 (platelet endo-
thelial cell adhesion molecule-1)–Alexa Fluor 488 (BioLegend,
London, United Kingdom) or anti-vascular endothelial-cadherin
(Santa Cruz Biotechnology, Dallas, TX, USA) and imaged using
a Cellomics VTi HCS Arrayscanner (Thermo Fisher Scientific,
Hemel Hempstead, United Kingdom).
Endothelial cell eicosanoid and cytokine production
Cells were plated on 48- or 96-well plates. For eicosanoid meas-
urements, endothelial cells were primed with IL-1b (1 ng/ml) to
up-regulate COX pathways, as described previously (28), before
being treated for 30minwithA23187 or thrombin to activate PLA2
or arachidonic acid to supply eicosanoid substrate directly. For
inflammation studies, endothelial cells were treated with vehicle
(Lonza EGM-2) or TLR ligands: heat-killed Listeria monocytogenes
(107 cells/ml), Pam3CSK4 (1mg/ml), FSL-1 (1mg/ml), poly(I:C)
(10mg/ml), LPS (1mg/ml), Staphylococcus aureus–derivedflagellin
(FLA; 100 ng/ml), imiquimod (1 mg/ml), single-stranded RNA
oligonucleotide-40 (1 mg/ml), and oligodeoxynucleotide-2006
(5 mM). After 24 h, media were collected for measurement of
CXCL8 release by ELISA (R&D Systems).
Statistics and data analysis
Data are expressed as means 6 SE. Statistical analysis was per-
formedby1- or 2-wayANOVAorbyunpairedStudent’s t testusing
GraphPad Prism 6 software (GraphPad Software, La Jolla, CA,
USA). Patient eicosanomics data (n = 1–2) were interpreted
qualitatively without statistical testing.
RESULTS
Role of cPLA2a in eicosanoid formation in platelets
Incubation of blood with collagen (Fig. 1A) or TRAP-6
(Fig. 1B) to specifically activate platelets increased levels
of TXB2 (the stable breakdown product of TXA2) and
12-HETE, in particular. There were also increases in
PGE2, prostaglandin D2 (PGD2), 11-HETE, and 15-HETE.
12-HETE levelswere somewhat lower inTRAP-6–stimulated
blood as compared with collagen-stimulated blood. In
blood treated with the Ca2+ ionophore, A23187, to cause
acute receptor-independent activation of platelets and
leukocytes, a broadly similar pattern of eicosanoid for-
mation was observed (Fig. 1C) with amarked production
of 12-HETE, followed by TXB2, 15-HETE, and 11-HETE.
There were also greatly increased levels of 5-HETE, rep-
resenting acute activation of leukocytes, and a more
modest production of 5,6-EET. In each case, eicosanoid
production to these stimuli was almost absent in blood
fromcPLA2a-deficient patients (Fig. 1 and Supplemental
Tables S1 and S2). Normal eicosanoid formation was
observed in the presence of exogenous arachidonic acid
in both healthy volunteer and cPLA2a-deficient patient
blood. In isolated platelets (platelet-rich plasma), TXB2
formation induced by ADP, collagen, or the TXA2-
mimeticU46619, but not exogenous arachidonic acid, was
abolished by cPLA2a deficiency (Supplemental Fig. S1).
Role of cPLA2a in platelet aggregation, secretion, and
adhesion responses
Absence of cPLA2a or cPLA2 inhibition by pyrrophenone
produced a marked reduction in collagen-induced ag-
gregation similar to that produced by aspirin (Fig. 2A)
but had little effect upon responses to ADP or exogenous
Figure 1. Contribution of cPLA2a to eicosanoid synthesis in
whole blood. Eicosanoid levels in whole blood from healthy
volunteers or from a patient lacking cPLA2a stimulated with
collagen (30 mg/ml) (A), TRAP-6 amide (30 mM) (B), or
A23187 Ca2+ ionophore (50 mM) (C). Levels are expressed as
increase over levels in vehicle-treated blood. n = 3–6 (healthy
volunteers); n = 1 (patient S).
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arachidonic acid (Fig. 2B). ATP release induced by col-
lagen (Fig. 2C), but not that induced by ADP or arachi-
donic acid (Fig. 2D), was strongly blunted by loss of
functional cPLA2a or aspirin treatment, and under flow
conditions, platelet adhesion to collagen was almost
abolished by cPLA2a inhibition/deficiency (Fig. 2E).
Role of cPLA2a in eicosanoid formation in
endothelial cells
Endothelial cells from healthy volunteers or derived from
cPLA2a-deficient patients emerged in culture after 4–20 d,
grew with typical cobblestone morphology, expressed the
endothelial cell markers CD31 and VE cadherin (Fig. 3A),
and aligned when cultured under directional shear stress
(29) (Fig. 3B). In the presence of A23187, endothelial cells
from healthy volunteers released predominately prostacy-
clin (measured as the stable breakdown product 6-keto-
PGF1a) followed by PGE2, PGD2, 11-HETE, and 15-HETE.
In each case, eicosanoid release was lower but not abol-
ished in endothelial cells derived from cPLA2a-deficient
patients (Fig. 3C) (e.g., prostacyclin release from cPLA2a-
deficient endothelial cells was reduced by ;80%). Simi-
larly, the cPLA2 inhibitor, pyrrophenone, produced a con-
centration-dependent inhibition of prostacyclin release
Figure 2. Effect of cPLA2a deficiency on platelet aggregation, secretion, and adhesion responses. Effect of cPLA2a deficiency,
cPLA2a inhibition, and aspirin on platelet aggregation to collagen (0.1–3 mg/ml) (A), ADP (5 mM) (B), and arachidonic acid
(AA; 1 mM) is shown. Pyrro, pyrrophenone. ATP secretion to collagen (0.1–3 mg/ml) (C), ADP (5 mM) (D), and arachidonic
acid (1 mM). E) Platelet adhesion to collagen under flow (1000 s21). n = 2–4 (healthy volunteers); n = 2 (patient B and patient S).
*P , 0.05 by 2-way ANOVA with Dunnett’s posttest.
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from endothelial cells grown from healthy donors
(Supplemental Fig. S2), with a maximal effect of ;80%.
Prostacyclin was also released from endothelial cells of
healthy volunteers when stimulated with the receptor-
dependent activator, thrombin (Fig. 3D). As described
forA23187-stimulated release above, thrombin-stimulated
prostacyclin release was reduced but not abolished in
cPLA2a-deficient patient endothelial cells. Endothelial
cells of both genotypes responded strongly to exogenous
arachidonic acid (Fig. 3D).
Role of cPLA2a in eicosanoid formation by leukocytes
When whole blood was stimulated (18 h) with the TLR4
agonist, LPS, to activate leukocytes and inducible bio-
synthetic pathways, the major eicosanoids produced were
12- and 15-HETE and PGE2, and a smaller amount of 11-
HETE (Fig. 4A and Supplemental Table S3). In cPLA2a-
deficient patient blood, LPS-induced production of PGE2
and15-HETEwas greatly reduced,whereas theproduction
of 12-HETE was little affected. Overall, productions were
restored by acute addition of arachidonic acid (Fig. 4B and
Supplemental Table S3). Pam3CSK4 (TLR2/1) and FSL-1
(TLR2/6), which activate pattern recognition receptors
associatedwithgram-positivebacteria, aswithLPS, activated
whole blood to release PGE2, an effect that was abolished
by cPLA2a deficiency (Fig. 4C). Neither Poly(I:C), which
stimulates the viral pathogen recognition receptor TLR3,
nor IL-1b, which works independently of pattern recog-
nition receptors, stimulated PGE2 release from whole
blood.
Role of cPLA2a in inflammatory responses in
endothelial cells and blood leukocytes
Whole blood from healthy volunteers treated with FSL-1,
Poly(I:C), or LPS, but not with IL-1b, released the in-
flammatory chemokine CXCL8 (Fig. 5A). Blood from
a cPLA2a-deficient patient exhibited more than 5-fold
greater responses to all agents except IL-1b as compared
withmatched controls (Fig. 5A). Treatment of blood from
healthy volunteers with the COX inhibitor diclofenac
suppressed theCXCL8 response toLPSbut did notmodify
CXCL8 release stimulated by other tested agents (Fig. 5A).
Endothelial cells from healthy donors also released
CXCL8 when stimulated with pathogen-associated molec-
ular patterns (PAMPs) directed at TLR2, 3, or 4, or with
IL-1b. Again, as with leukocytes in whole blood, endothe-
lial cells from a cPLA2a-deficient patient released ele-
vated levels of CXCL8 when stimulated with inflammatory
Figure 3. Phenotyping of and eicosanoid synthesis by endothelial cells grown out of blood progenitors from healthy volunteers
and from a cPLA2a-deficient patient. A) Endothelial-specific marker expression of CD31 (green) and VE cadherin (red) and
actin staining (green). B) Morphologic response to shear stress after 3 d. C) Eicosanoid release in IL-1b (1 ng/ml)-primed
endothelial cells stimulated with A23187 (50 mM). D) Prostacyclin release from IL-1b–primed endothelial cells stimulated for
30 min with A23187 (50 mM), thrombin (1 U/ml), or arachidonic acid (AA; 50 mM). Data are from at least 3 wells per condition.
n = 3–6 (healthy volunteers); n = 1 (patient S).
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agents (Fig. 5B). Endothelial cells from either type of
donor did not respond to ligands for TLR5, TLR7, or
TLR8 (Fig. 5B).
Involvement of cPLA2a in plasma and urinary
eicosanoid levels
Plasma from healthy volunteers contained primarily
metabolites of linoleic acid, eicosapentaenoic acid (EPA),
and docosahexaenoic acid (DHA). Patients lacking
cPLA2a had reduced levels of these mediators compared
with plasma from healthy volunteers (Fig. 6A). Basal
plasma also contained substantial levels of 12-HETE, and
this remained in cPLA2a-deficient patient plasma.
Absence of cPLA2a was associated with strong reduc-
tions in the levels of leukotriene E4 (LTE4) and prostacy-
clin metabolites (Fig. 6B, C), whereas substantial levels of
PGD2, PGE2, and8-isoprostanemetabolites remained (Fig.
6D–G). Levels of the urinary metabolite of thromboxane
A2 (TX-M)were 50% lower in cPLA2a-deficient patients as
compared with healthy volunteers (0.202 6 0.010 ng/mg
creatinine vs. 0.101 6 0.017 ng/mg creatinine; P , 0.01;
Fig. 6E). In addition, substantial levels of PGD2, PGE2, and
8-isoprostanemetabolites remained in urine samples from
cPLA2a-deficient patients.
DISCUSSION
Here, we have examined the contribution of cPLA2a to
eicosanoid formation, and thrombotic and inflammatory
responses in platelets, blood leukocytes, and endothelial
cells from 2 individuals with a unique genetic inactivation
of this enzyme. Although we (18) and others (19, 20) have
published reports of individuals lacking functional cPLA2a,
including limited analysis of platelet responses, this is the
first time a full and systematic eicosanoid analysis has
been undertaken on samples from these patients and
considered in the context of the circulatory system in
health and inflammation. These data demonstrate an
absolute requirement for cPLA2a in eicosanoid synthesis
in the vascular compartment with a consequent loss of
Figure 4. Contribution of cPLA2a to eicosanoid synthesis in
leukocytes. A) Eicosanoid levels in whole blood from healthy
volunteers or from a patient lacking cPLA2a treated with LPS
(10 mg/ml) for 18 h. PGE2 formation in whole blood treated
with LPS (10 mg/ml) for 18 h followed by addition of A23187
(50 mM) or arachidonic acid (AA; 1 mM) for 30 min (B) or
treated with agonists to TLR2/1 (Pam3CSK4; 1 mg/ml),
TLR2/6 (FSL-1; 1 mg/ml), TLR3 [poly(I:C); 10 mg/ml], IL-1
receptor (IL-1b; 1 ng/ml), or TLR4 (LPS; 5–20 mg/ml) (C).
n = 3–6 (healthy volunteers); n = 1 (patient S).
Figure 5. Effect of cPLA2a deficiency on blood leukocyte and
endothelial cell inflammatory responses. A) CXCL8 release in
whole blood from healthy volunteers with or without pre-
treatment with the COX inhibitor diclofenac (Diclo; 10 mM)
or a cPLA2a-deficient patient in response to agonists to
TLR2/1 (Pam3CSK4; 1 mg/ml), TLR2/6 (FSL-1; 1 mg/ml),
TLR3 [poly(I:C); 10 mg/ml], TLR4 (LPS; 1 mg/ml), or IL-1
receptor (IL-1b; 1 ng/ml). B) CXCL8 release by endothelial
cells to agonists of TLR2 [heat-killed L. monocytogenes (HKLM);
107 cells/ml], TLR2/1 (Pam3CSK4; 1 mg/ml), TLR2/6 (FSL-1;
1 mg/ml), TLR3 [poly(I:C); 10 mg/ml], TLR4 (LPS; 10 mg/ml),
TLR5 (FLA; 100 ng/ml), TLR7 (imiquimod; 1 mg/ml),
TLR8 [single-stranded RNA oligonucleotide-40 (ssRNA40);
1 mg/ml], TLR9 [oligodeoxynucleotide-2006 (ODN2006);
5 mM], or IL-1 receptor (IL-1b; 1 ng/ml). n = 3–6 (healthy
volunteers; 2 determinations each); n = 1 (patient S; 3 de-
terminations each). *P , 0.05 by 2-way ANOVA with Dunnett’s
posttest.
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platelet activation pathways, reduced antithrombotic
prostacyclin, and increased inflammatory sensitivity of
both endothelial cells and leukocytes.
Platelets
The PLA2 system in platelets is among the most clearly
defined in cardiovascular cell types. We and others have
previously performed limited phenotyping of platelets
fromcPLA2a-deficient individuals and founda requirement
for this enzyme in TXA2 formation and collagen-induced
platelet aggregation, which is TXA2 dependent. How-
ever, in addition to cPLA2a, platelets also express sPLA2,
which others suggest contributes to eicosanoid forma-
tion in platelets (9, 10, 30). Here, for the first time, we
have performed a full eicosanomic analysis of samples
from cPLA2a-deficient individuals to consider the role
of this enzyme in synthesis of a range of functional dis-
tinct arachidonic acid–derived mediators. Stimulation
of whole blood with the platelet activators collagen or
TRAP-6 resulted in greatly increased synthesis of TXA2,
in addition to PGE2, PGD2, and 11-, 12-, and 15-HETE,
mediators primarily produced by COX and LOX path-
ways. 12-HETE levels were somewhat lower in TRAP-
6–stimulated blood as compared to collagen-stimulated
blood, consistent with reports that 12-LOX activation is
linked to the platelet collagen receptor, glycoprotein VI
(7). Stimulation of blood with the receptor-independent
activator Ca2+ ionophore A23187 produced a similar
platelet eicosanoid fingerprint, but unlike collagen and
TRAP-6, increased levels of 5-HETE, reflecting acute ac-
tivation of leukocytes. In each case, eicosanoid production
was cPLA2a dependent because it was lost in cPLA2a-
deficient patient blood but reversed by the addition of
exogenousarachidonic acid,demonstrating itsdependence
on loss of endogenous substrate release. In agreement, iso-
lated cPLA2a-deficient platelets stimulated with a range of
agonists (collagen, ADP, and U46619), but not exogenous
arachidonic acid, exhibited a complete loss of TXA2 syn-
thesis, in contrast to reports that ADP-induced release is not
altered in cPLA2a-knockoutmouseplatelets (9).Thesedata
Figure 6. Contribution of cPLA2a to basal plasma and urinary eicosanoid levels. A) Basal eicosanoid levels in plasma from healthy
volunteers (circles) or from a patient lacking cPLA2a. n = 8 (healthy volunteers; 2 determinations each); n = 2 (patient B and
patient S; 2 determinations each). Urinary levels of LTE4 (B) and metabolites of prostacyclin (PGI-M) (C), 8-isoprostane (8iso-M)
(D), TXA2 (TX-M) (E), PGD2 [tetranor (tn)PGD-M] (F), and PGE2 (PGE-M) (G) in healthy volunteers (filled columns) or from
patients lacking cPLA2a (unfilled columns). n = 7 (healthy volunteers; 2 determinations each); n = 2 (patient B and patient S;
4 determinations each).
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illustrate the requirement for cPLA2a in the full range of
eicosanoids synthesized by platelets and that this is in-
dependent of the stimulus used (9, 10).
We next set out to establish the contribution of cPLA2a-
derived eicosanoids to functional platelet aggregation re-
sponses. Although it is well known that the platelet COX
product TXA2 is a powerful proaggregatory agent, this re-
sponse may be modified by other eicosanoid mediators
synthesized inparallel. Indeed,PGE2(31),12-HETE(32–34),
15-HETE (35), and 5,6-EET (36) increase platelet acti-
vation, whereas PGD2 (37) and higher levels of PGE2may
limit platelet activation (31), meaning the net contribu-
tion of cPLA2a-derived eicosanoids is unclear. Our stud-
ies using traditional light transmission lumi-aggregometry
and 96-well plate aggregometry demonstrated that in-
hibition or absence of cPLA2a produced a marked re-
duction in collagen-induced platelet aggregation and
dense granule (ATP) secretion, in agreement with what
we (18) and others (9, 19, 20) have previously reported.
These defects were rescued by exogenous arachidonic
acid, demonstrating that they were specifically associated
with loss of endogenous substrate release. Similarly,
platelet adhesion to a collagen-coated surface in flowing
blood was abolished by cPLA2 inhibition and absent in
blood from cPLA2a-deficient patients. These data are in
agreement with reports of the importance of cPLA2a and
TXA2 generation in platelet adhesion (38). In each of
these functional assays, the reduction observed was similar
to that produced by the COX inhibitor aspirin, suggesting
that regulation of collagen-induced platelet responses by
cPLA2a is due to products of platelet COX-1, probably
TXA2. Overall, these data show that cPLA2a is absolutely
required for formationof eicosanoidmediators in platelets
and thatdespite the synthesisof several eicosanoid families,
the contribution of cPLA2a to platelet aggregation, secre-
tion, and adhesion responses canbe entirely accounted for
by generation of COXproducts. This reduction in platelet
function is consistent with an increased tendency to
bruising noted in the clinical care of these patients.
Endothelium
Through eicosanoid release, endothelial cells are key to
health and disease of the circulation. Here, we have made
use of endothelial cells isolated from blood progenitors
providing the first opportunity to study genetic deficiency
of cPLA2a in human endothelium. Endothelial cells from
a cPLA2a-deficient patient expressed the normal endo-
thelial cellmarkersCD31andvascularendothelial-cadherin,
had a cobblestone morphology, and when cultured un-
der conditions of chronic (3 d) laminar shear stress (29),
aligned with the direction of shear, demonstrating their
endothelial phenotype. When we examined eicosanoid
production by endothelial cells, A23187 stimulation in-
creased production of several eicosanoid mediators, the
most abundant of which was prostacyclin, with lower
levels of PGE2, PGD2, and 11-, 12-, and 15-HETE. These
were predominantly driven by cPLA2a because they were
strongly reduced in cPLA2a-deficient endothelial cells.
This was further confirmed by the ability of a selective
cPLA2 inhibitor toprevent themajorityofA23187-stimulated
prostacyclin production by endothelial cells and was
specific because cPLA2a-deficient endothelial cells
responded normally to exogenous arachidonic acid.
However, cPLA2a-deficient endothelial cells stimu-
lated with either A23187 or thrombin continued to
produce some prostacyclin, probably reflecting con-
tribution of other PLA2 isoforms [e.g., group VIA iPLA2
(also referred to as iPLA2b)] to eicosanoid generation
in endothelium (11, 12).
Leukocytes and inflammation
In parallel with platelet and endothelial cell studies, we
examined the effect of addition of inflammatory stimuli
(e.g., LPS) to whole blood to investigate the role of cPLA2a
in blood leukocyte responses, an approach frequently ap-
plied in the eicosanoidfield (3, 39).Whenwholebloodwas
stimulated with A23187, in addition to platelet-derived
mediators, 5-HETE was detected, which is associated with
5-LOX present in monocytes and neutrophils (40). When
blood was stimulated with LPS to specifically activate
leukocytes and inducible biosynthetic pathways such as
COX-2, a more characteristic inflammatory eicosanoid
profile was produced with PGE2, 12- and 15-HETE being
the most abundant products. In each case, eicosanoid
synthesiswas cPLA2amediated. In cPLA2a-deficientpatient
blood, LPS-induced production of PGE2 and 15-HETE was
greatly reduced, and overall, productions were restored by
acute addition of arachidonic acid, confirming that this
defect is due to loss of free endogenous arachidonic
acid. In contrast, in LPS-stimulated blood, the pro-
duction of 12-HETE was little affected by cPLA2a de-
ficiency, suggesting that other PLA2 isoforms specifically
couple to 12-HETE synthesis in blood leukocytes. By its
actions onTLR4, LPSmimics the effects of gram-negative
bacteria. However, other pathogens activate immune
and inflammatory responses in tissues through different
pattern recognition receptor signaling pathways, each of
which could theoretically drive eicosanoid production by
different PLA2 isoforms. To address this, we studied the
effect of a full range of PAMPs that mimic gram-positive,
as well as gram-negative, bacteria or viruses. Thus,
Pam3CSK4 (TLR2/1) and FSL-1 (TLR2/6), which acti-
vate pattern recognition receptors associated with gram-
positive bacteria, as with LPS, activated whole blood to
release PGE2, an effect that was abolished by cPLA2a
deficiency. Neither Poly(I:C), which stimulates the viral
pathogen recognition receptor TLR3, nor IL-1b, which
works independently of pattern recognition receptors,
stimulated PGE2 release from whole blood. Although
these data demonstrate that cPLA2a is central to leuko-
cyte eicosanoid synthesis, particularly for PGE2, there are
clearly roles for other PLA2 isoforms such as sPLA2 (13).
To understand the implications of loss of eicosanoid
production to the inflammatory response, we measured
CXCL8 production, induction of which reflects both pri-
mary activation of inflammatory transcriptional pathways
such as NF-kB pathways and subsequent secretion of TNF-
a and IL-1b (20, 41).Whole blood fromhealthy volunteers
treated with FSL-1, Poly(I:C), or LPS, but not with IL-1b,
released the inflammatory chemokine CXCL8. Blood
from a cPLA2a-deficient patient exhibited more than
5-fold greater responses to all agents except IL-1b as
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compared with matched controls (Fig. 5A). Treatment of
blood from healthy volunteers with the COX inhibitor
diclofenac suppressed the CXCL8 response to LPS but did
not modify CXCL8 release stimulated by other tested
agents (Fig. 5A), indicating that the effect was not medi-
ated by loss of COX metabolites. Although it cannot be
excluded that cPLA2a-deficient patient blood contains
altered leukocyte subsets, blood constituents, or other
confounding influences, these data suggest that cPLA2a-
dependent mediators, other than COX products, act to
suppress cytokine responses by blood leukocytes. This ef-
fect may reflect loss of 11- and/or 15-HETE synthesis be-
cause these were also detected in LPS-stimulated whole
blood, and it has been previously reported that 15-HETE
has anti-inflammatory activity (42, 43).
Similarly, endothelial cells fromhealthy donors released
CXCL8 when stimulated with PAMPs directed at TLR2, 3,
or 4, or with IL-1b. As with leukocytes in whole blood,
endothelial cells from a cPLA2a-deficient patient released
elevated levels of CXCL8 when stimulated with in-
flammatory agents, consistent with activation of NF-kB
pathways following treatmentwith inflammatory stimuli, as
we have previously described (25). Endothelial cells from
either type of donor did not respond to ligands for TLR5,
the pattern recognition receptor for motile bacteria and
fungi, TLR7 and TLR8, pattern recognition receptors for
single-strandedRNA viruses, or TLR9, which is the pattern
recognition receptor for bacterial DNA. Importantly, in
contrast to blood leukocyte studies, these endothelial cells
constitutea single, definedcell type ina controlledmedium
suggesting that any differences observed likely reflect
changes in eicosanoid production as compared to con-
founding factors present in blood cells. Because prostacy-
clin was the most abundant eicosanoid produced by
endothelial cells and is a powerful inhibitor of vascu-
lar inflammation, this proinflammatory phenotype of
cPLA2a-deficient endothelial cells is most easily explained
by loss of this fundamental vascular hormone. CXCL8 is
a potent neutrophil chemotactic factor, which has been
implicated in atherogenesis (44); thus, augmented pro-
duction of CXCL8 and potentially other NF-kB–driven
cytokines is likely to be detrimental to cardiovascular
health. Moreover, taken together, these studies demon-
strate that on a global level, blood leukocytes and endo-
thelial cells require cPLA2a to produce eicosanoids in
response to a range of inflammatory stimuli, and this exerts
both COX-dependent and possibly COX-independent
regulation of cytokine production and, by inference,
immunologic/inflammatory defenses, consistent with
clinical manifestations in these patients (18, 19).
Production in vivo
Finally, to provide an overview of the contribution of
cPLA2a to eicosanoid formation from all sources in the
body, we measured the eicosanoid profile in plasma and
specific urinary eicosanoid metabolites. Plasma from
healthy volunteers contained low levels of primarily
metabolites of linoleic acid, EPA, and DHA. Patients
lacking cPLA2a had reduced levels of these mediators
compared with plasma from healthy volunteers. Because
cPLA2a has strong specificity for arachidonate-containing
phospholipids, thismay reflect altered physiology in these
patients. Notably, basal plasma also contained substantial
levels of 12-HETE, which may reflect platelet activation
during blood sampling; as noted above, 12-HETE is the
majorproduct of activatedplatelets.However, surprisingly,
a small 12-HETE peak was also seen in cPLA2a-deficient
patient plasma, suggesting possible cPLA2a-independent
eicosanoid formation in the body.
Interpretation of plasma eicosanoid data as representa-
tive of a circulating pool is difficult because levels may re-
flect local vascular activation during blood sampling, and
many eicosanoids rapidly degrade/clear from the circula-
tion. For this reason, many favor measurement of urinary
metabolites to assess in vivo eicosanoid production. Using
this approach, we observed that absence of cPLA2a was
associated with strong reductions in the levels of LTE4,
prostacyclin, and TXA2 metabolites, consistent with the
reductions in TXA2 production by platelets, prostacyclin
production by endothelial cells, and 5-HETE production
by monocytes/neutrophils [LTE4 is a downstream meta-
bolite of 5-LOXproducts (40)] that we noted in our in vitro
cell studies.Ofparticular relevance toplatelet functionwas
the urinary TXA2 metabolite, TX-M. This has been often
recommendedas amarkerof platelet activation in vivo that
could be used to gauge the efficacy of aspirin treatment
and the level of ongoing platelet activation (45).We noted
that whereas platelets from cPLA2a-deficient patients did
not produce TXA2, urinary levels of TX-M in the patients
were reduced only by ;50%. This demonstrates that uri-
nary TX-M does not specifically report production from
platelets and adds to a growing body of evidence ques-
tioning the origin of TX-M and other urinary prostanoid
metabolites (23, 46). In addition, substantial levels of
PGD2, PGE2, and 8-isoprostane metabolites remained in
urine samples from cPLA2a-deficient patients, further
suggesting that there are sites in the body where consid-
erable cPLA2a-independent prostanoid formation occurs.
CONCLUSIONS
Here, we have examined the contribution of cPLA2a to
eicosanoid formation, and thrombotic and inflammatory
responses in platelets, blood leukocytes, and endothelial
cells from individuals with a unique genetic inactivation of
this enzyme. Our data demonstrate an absolute require-
ment for cPLA2a in eicosanoid synthesis in the vascular
compartment with a consequent loss of platelet activation
pathways, reduced antithrombotic prostacyclin, and in-
creased inflammatory sensitivity of both endothelial cells
and leukocytes. This study unites many conflicting obser-
vations in the literature and provides a definitive account of
the rate-limiting and perhaps most fundamental compo-
nent of this system, cPLA2a.
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Figure S1. Effect of cPLA2 deficiency on platelet TXA2 release to a range of agonists. TXA2 release (measured as 
TXB2) by platelet-rich plasma from healthy volunteer or cPLA2ɑ-deficient patients (patient B + patient S) blood in 
response to stimulation by collagen (0.3-3 µg/ml), ADP (5 µmol/L), U46619 (10 µmol/L) or arachidonic acid (1mmol/L). 





Figure S2. Effect of cPLA2 inhibition on prostacyclin release by endothelial cells. Prostacyclin release (measured as 6-
keto-PGF1α) by endothelial cells isolation from healthy volunteer or cPLA2ɑ -deficient patient  (patient S) blood in 
response to A23187 stimulation in the presence of increasing concentrations of the cPLA2 inhibitor, pyrrophenone. n=4 






	   2 











6ketoPGF1α 0.0 ± 0.0 0.0 0.1 ± 0.0 0.1 0.1 ± 0.0 0.0 0.2 ± 0.1 0.0 
TXB2 0.1 ± 0.0 0.0 17.6 ± 3.1 0.1 24.1 ± 7.5 0.0 38.4 ± 4.4 0.1 
PGE2 0.0 ± 0.0 0.0 1.1 ± 0.2 0.0 2.0 ± 1.0 0.0 4.8 ± 1.2 0.0 
PGD2 0.0 ± 0.0 0.0 0.8 ± 0.2 0.0 1.1 ± 0.5 0.0 2.7 ± 0.6 0.0 
8isoPGF2α 0.0 ± 0.0 0.0 0.1 ± 0.0 0.0 0.1 ± 0.0 0.0 0.1 ± 0.0 0.0 
9,12,13-THOME 1.2 ± 0.9 0.2 0.3 ± 0.1 0.2 1.2 ± 1.0 0.2 1.2 ± 0.9 0.2 
9,10,13-THOME 0.1 ± 0.0 0.1 0.1 ± 0.0 0.1 0.1 ± 0.0 0.0 0.2 ± 0.0 0.0 
12,13-DHOME 13.8 ± 4.6 2.5 15.0 ± 5.7 3.0 15.8 ± 5.5 1.9 17.3 ± 7.0 1.8 
9,10-DHOME 7.6 ± 2.4 2.4 8.1 ± 2.7 2.7 8.8 ± 3.1 1.7 9.8 ± 3.2 1.2 
19,20-DiHDPA 0.9 ± 0.2 1.2 0.9 ± 0.2 1.3 1.0 ± 0.2 0.9 0.9 ± 0.2 0.8 
14,15-DHET 0.5 ± 0.0 0.3 0.5 ± 0.0 0.3 0.5 ± 0.0 0.2 0.5 ± 0.0 0.2 
11,12-DHET 0.3 ± 0.0 0.1 0.3 ± 0.0 0.1 0.3 ± 0.0 0.1 0.3 ± 0.0 0.1 
8,9-DHET 0.1 ± 0.0 0.1 0.1 ± 0.0 0.1 0.2 ± 0.0 0.1 0.2 ± 0.0 0.1 
5,6-DHET 0.1 ± 0.0 0.1 0.1 ± 0.0 0.1 0.1 ± 0.0 0.0 0.2 ± 0.1 0.0 
13-HODE 1.8 ± 0.3 0.6 2.0 ± 0.3 0.7 2.0 ± 0.3 0.6 3.4 ± 0.6 0.6 
9-HODE 0.8 ± 0.1 0.2 1.0 ± 0.1 0.2 1.1 ± 0.2 0.1 1.5 ± 0.1 0.1 
20-HETE 0.3 ± 0.1 0.1 0.3 ± 0.1 0.0 0.3 ± 0.1 0.1 0.4 ± 0.1 0.0 
19-HETE 0.3 ± 0.0 0.2 0.3 ± 0.0 0.2 0.3 ± 0.0 0.1 0.3 ± 0.0 0.1 
15-HETE 0.7 ± 0.1 0.5 10.5 ± 2.2 0.6 14.2 ± 4.9 0.4 34.5 ± 2.5 0.7 
12-HETE 8 ± 5 2.8 235 ± 64 6.0 43 ± 19 2.9 838 ± 90 25.7 
11-HETE 0.1 ± 0.0 0.1 4.1 ± 0.8 0.1 6.2 ± 2.4 0.0 11.3 ± 1.3 0.1 
5-HETE 0.7 ± 0.2 0.4 1.3 ± 0.3 0.5 1.2 ± 0.2 0.3 217 ± 39 0.3 
12,13-EpOME 2.9 ± 0.6 0.8 2.6 ± 0.4 0.8 2.8 ± 0.5 0.8 2.8 ± 0.5 1.0 
9,10-EpOME 0.3 ± 0.1 0.2 0.3 ± 0.0 0.2 0.3 ± 0.1 0.2 0.4 ± 0.1 0.3 
19,20-EpDPE 0.4 ± 0.1 0.8 0.5 ± 0.1 1.0 0.5 ± 0.1 0.8 0.6 ± 0.1 0.7 
17,18-EpETE 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 
14,15-EET 0.1 ± 0.0 0.0 0.1 ± 0.0 0.1 0.1 ± 0.0 0.0 0.4 ± 0.0 0.1 
11,12-EET 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 0.2 ± 0.0 0.0 
8,9-EET 0.1 ± 0.0 0.0 0.1 ± 0.0 0.1 0.1 ± 0.0 0.0 0.2 ± 0.0 0.0 
5,6-EET 0.4 ± 0.1 0.2 0.6 ± 0.1 0.3 0.7 ± 0.1 0.2 2.4 ± 0.1 0.4 
 
Table S1. Contribution of cPLA2α to eicosanoid synthesis in whole blood stimulated with platelet activators. Total 
eicosanoid levels in whole blood from healthy volunteers (‘control’) or from patient S lacking cPLA2α (‘cPLA2α 
deficient’) stimulated with vehicle (PBS), collagen (30µg/ml), TRAP-6 amide (30µM) or Ca2+ ionophore A23187 (30µM). 
n=4 (healthy volunteers), n=1 (patient). 
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 Vehicle (PBS) AA (1mM) 
Mediator 
(ng/ml) Control cPLA2α deficient Control cPLA2α deficient 
6ketoPGF1α 0.0 ± 0.0 0.0 2.5 ± 0.6 0.5 
TXB2 0.1 ± 0.0 0.0 168.0 ± 12.1 83.3 
PGE2 0.0 ± 0.0 0.0 144.7 ± 38.8 30.1 
PGD2 0.0 ± 0.0 0.0 143.1 ± 46.5 35.0 
8isoPGF2α 0.0 ± 0.0 0.0 14.3 ± 5.9 0.8 
9,12,13-THOME 1.2 ± 0.9 0.2 1.4 ± 0.5 0.2 
9,10,13-THOME 0.1 ± 0.0 0.1 0.9 ± 0.4 0.1 
12,13-DHOME 13.8 ± 4.6 2.5 18.0 ± 2.9 2.4 
9,10-DHOME 7.6 ± 2.4 2.4 17.2 ± 7.2 2.2 
19,20-DiHDPA 0.9 ± 0.2 1.2 1.0 ± 0.1 1.1 
14,15-DHET 0.5 ± 0.0 0.3 23.8 ± 6.0 6.7 
11,12-DHET 0.3 ± 0.0 0.1 14.1 ± 2.9 6.4 
8,9-DHET 0.1 ± 0.0 0.1 8.0 ± 2.7 2.1 
5,6-DHET 0.1 ± 0.0 0.1 41.9 ± 16.7 11.6 
13-HODE 1.8 ± 0.3 0.6 13.3 ± 5.3 0.7 
9-HODE 0.8 ± 0.1 0.2 12.4 ± 5.6 0.4 
20-HETE 0.3 ± 0.1 0.1 6.3 ± 0.4 5.1 
19-HETE 0.3 ± 0.0 0.2 9.6 ± 3.8 1.7 
15-HETE 0.7 ± 0.1 0.5 1945.3 ± 484.6 813.3 
12-HETE 8.5 ± 5.1 2.8 1448.3 ± 228.7 1060.0 
11-HETE 0.1 ± 0.0 0.1 301.1 ± 83.3 129.3 
5-HETE 0.7 ± 0.2 0.4 520.0 ± 148.3 298.7 
12,13-EpOME 2.9 ± 0.6 0.8 4.1 ± 0.8 0.7 
9,10-EpOME 0.3 ± 0.1 0.2 1.2 ± 0.5 0.2 
19,20-EpDPE 0.4 ± 0.1 0.8 1.1 ± 0.5 1.0 
17,18-EpETE 0.0 ± 0.0 0.0 0.2 ± 0.1 0.1 
14,15-EET 0.1 ± 0.0 0.0 149.8 ± 36.8 66.3 
11,12-EET 0.0 ± 0.0 0.0 113.5 ± 34.9 38.7 
8,9-EET 0.1 ± 0.0 0.0 115.9 ± 42.2 40.9 
5,6-EET 0.4 ± 0.1 0.2 471.8 ± 201.7 200.3 
 
Table S2. Contribution of cPLA2α to eicosanoid synthesis in whole blood stimulated with exogenous arachidonic 
acid (AA). Total eicosanoid levels in whole blood from healthy volunteers (‘control’) or from patient S, lacking cPLA2α 
(‘cPLA2α deficient’) stimulated with vehicle (PBS) or exogenous AA (1mM). n=4 (healthy volunteers), n=1 (patient). 
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6ketoPGF1α 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 0.3 ± 0.0 0.1 
TXB2 0.6 ± 0.3 0.0 2.5 ± 0.4 0.3 128.1 ± 12.9 35.2 
PGE2 5.7 ± 5.3 0.1 26.2 ± 6.7 2.0 161.6 ± 25.3 55.4 
PGD2 0.1 ± 0.0 0.0 0.2 ± 0.1 0.1 140.9 ± 5.2 105.1 
8isoPGF2α 0.0 ± 0.0 0.0 0.2 ± 0.0 0.0 2.7 ± 0.2 1.4 
9,12,13-THOME 0.7 ± 0.5 0.2 0.7 ± 0.4 0.3 0.7 ± 0.4 0.3 
9,10,13-THOME 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 0.1 ± 0.0 0.1 
12,13-DHOME 21.8 ± 5.6 3.0 19.6 ± 3.8 3.9 12.0 ± 6.3 3.6 
9,10-DHOME 9.6 ± 3.2 2.5 8.5 ± 3.0 3.6 5.1 ± 3.0 0.9 
19,20-DiHDPA 2.2 ± 0.5 2.9 2.1 ± 0.2 2.8 1.4 ± 0.6 1.9 
14,15-DHET 0.7 ± 0.1 0.6 0.8 ± 0.1 0.5 8.9 ± 6.2 5.7 
11,12-DHET 1.1 ± 0.1 0.5 0.8 ± 0.1 0.7 7.7 ± 5.2 6.2 
8,9-DHET 1.2 ± 0.1 0.9 1.3 ± 0.1 0.6 7.4 ± 3.3 5.1 
5,6-DHET 1.3 ± 0.2 0.5 1.3 ± 0.1 0.8 50.1 ± 23.9 23.9 
13-HODE 16.8 ± 3.8 7.3 30.9 ± 9.7 20.7 12.8 ± 4.3 19.0 
9-HODE 4.9 ± 1.1 1.6 5.3 ± 1.5 4.1 3.8 ± 1.6 0.5 
20-HETE 0.8 ± 0.4 0.0 0.6 ± 0.2 0.0 9.9 ± 3.9 9.6 
19-HETE 0.5 ± 0.3 0.0 0.8 ± 0.4 1.2 18.1 ± 6.3 18.8 
15-HETE 11.9 ± 4.7 5.9 34.8 ± 8.6 12.5 2787 ± 1116 3386.7 
12-HETE 215.0 ± 50.2 71.5 229.2 ± 70.6 98.1 1758 ± 1029 2082.0 
11-HETE 3.6 ± 2.1 0.7 8.8 ± 4.2 2.5 400 ± 213.9 595.3 
5-HETE 4.5 ± 2.0 2.3 4.8 ± 1.0 2.4 797.1 ± 359.8 1045.3 
12,13-EpOME 2.8 ± 0.5 1.7 2.7 ± 0.7 1.9 1.8 ± 0.5 1.8 
9,10-EpOME 0.6 ± 0.1 0.5 0.6 ± 0.2 0.6 0.4 ± 0.1 0.6 
19,20-EpDPE 1.3 ± 0.2 4.4 1.6 ± 0.2 4.8 1.4 ± 0.5 5.2 
17,18-EpETE 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 
14,15-EET 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 63.3 ± 18.1 61.0 
11,12-EET 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 25.8 ± 9.1 33.9 
8,9-EET 0.0 ± 0.0 0.0 0.0 ± 0.0 0.0 32.2 ± 11.6 40.3 
5,6-EET 0.3 ± 0.3 0.0 0.5 ± 0.3 0.0 119.1 ± 36.6 125.8 
 
Table S3. Contribution of cPLA2α to eicosanoid synthesis in whole blood stimulated with LPS. Total eicosanoid 
levels in whole blood from healthy volunteers (‘control’) or from patient S lacking cPLA2α (‘cPLA2α deficient’) 
stimulated for 18 hours with vehicle (DMEM) or LPS (10µg/ml) with or without addition of exogenous arachidonic acid 
(AA; 1mM) for the final 30 mins. n=4 (healthy volunteers), n=1 (patient). 
